Search by Drug Name or NDC
NDC 80725-0243-30 Aciphex 20 mg/1 Details
Aciphex 20 mg/1
Aciphex is a ORAL TABLET, DELAYED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Waylis Therapeutics LLC. The primary component is RABEPRAZOLE SODIUM.
MedlinePlus Drug Summary
Rabeprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube that connects the throat and stomach) in adults and children 12 year of age and older. Rabeprazole is used to treat damage from GERD, allow the esophagus to heal, and prevent further damage to the esophagus in adults. Rabeprazole is also used to treat conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome in adults. Rabeprazole is used to treat ulcers (sores in the lining of the stomach or intestine) and is used in combination with other medications to eliminate H. pylori (a bacteria that causes ulcers) in adults. Rabeprazole is in a class of medications called proton-pump inhibitors. It works by decreasing the amount of acid made in the stomach.
Related Packages: 80725-0243-30Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Rabeprazole
Product Information
| NDC | 80725-0243 |
|---|---|
| Product ID | 80725-243_a7e7efb0-65cc-403b-9de2-a2b328f6c908 |
| Associated GPIs | |
| GCN Sequence Number | 040941 |
| GCN Sequence Number Description | rabeprazole sodium TABLET DR 20 MG ORAL |
| HIC3 | D4J |
| HIC3 Description | PROTON-PUMP INHIBITORS |
| GCN | 94639 |
| HICL Sequence Number | 018847 |
| HICL Sequence Number Description | RABEPRAZOLE SODIUM |
| Brand/Generic | Brand |
| Proprietary Name | Aciphex |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | rabeprazole sodium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, DELAYED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/1 |
| Substance Name | RABEPRAZOLE SODIUM |
| Labeler Name | Waylis Therapeutics LLC |
| Pharmaceutical Class | Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020973 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 80725-0243-30 (80725024330)
| NDC Package Code | 80725-243-30 |
|---|---|
| Billing NDC | 80725024330 |
| Package | 30 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (80725-243-30) |
| Marketing Start Date | 2023-12-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |